GS-9716 for Solid Tumors
Study Summary
This trial is studying the side effects of a new drug called GS-9716 when given alone or with other drugs to treat patients with solid tumors that have spread to other parts of the body.
- Solid Tumors
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Are there still opportunities for prospective participants in this trial?
"Confirmed. According to information on clinicaltrials.gov, this trial is currently enrolling participants with the original post date of September 15th 2021 and a recent update from November 10th 2022. There are 5 sites recruiting over 200 patients in total."
Has GS-9716 been accorded official sanction by the FDA?
"The safety of GS-9716 is appraised as a 1 since this Phase 1 trial has only collected limited proof for its efficacy and security."
What have been the other research endeavors associated with GS-9716?
"Presently, 752 clinical trials are actively underway for GS-9716 with 247 of these in their final phase. Most of the studies have been set up at a location within Woolloongabba, Queensland yet there exists an expansive network of 42846 sites conducting research on this therapeutic agent."
For what conditions has GS-9716 demonstrated effectiveness?
"GS-9716 is a viable therapeutic option for neoplasm metastasis, as well as metastatic bladder cancer, advance directives, and urinary bladder."
How many participants does this research involve?
"Gilead Sciences, the trial's sponsor, will be recruiting 205 appropriately qualified patients from START Mountain Region in Grand Rapids and START San Antonio in Texas."
How many settings is this experiment supervised in?
"START Mountain Region in Grand Rapids, Michigan, START San Antonio in San Antonio, Texas and START Midwest in Portland Oregon are a few centres recruiting participants for this medical research. Additionally, there are 5 other clinical sites participating."